Arterial hypertension and diabetes mellitus are comorbid diseases, they are interconnected not only by common pathophysiological mechanisms of development, but also by similar cardiovascular complications. This relationship is due to the activation of the renin-angiotensin-aldosterone system, which underlies the remodeling of the cardiovascular system and the development of complications. According to current clinical guidelines, ACE inhibitors are the drugs of choice for the treatment of hypertension in combination with diabetes mellitus. The use of ACE inhibitors in patients with hypertension and diabetes is accompanied by a decrease in the relative risk of cardiovascular outcomes and mortality. This article presents the results of a clinical study of the combined drug Co-ramaz (ramipril and hydrochlorothiazide) in elderly patients with arterial hypertension and diabetes mellitus.
Balabolkin M.I., Mamaeva G.G., Kravchenko T.V., Muzychenko V.G. Arterial hypertension in patients with diabetes mellitus (a manual for physicians). - M.: Medicine, 2003. - 69 p.
Boitsov S.A., Balanova Yu.A., Shalnova S.A. Arterial hypertension among persons aged 25–64 years: prevalence, awareness,
treatment and control. Based on the ESSE study. Cardiovascular therapy and prevention. 2014; 13(4): 4-14.
Konradi A.O., Nedogoda S.V., Nedoshivin A.O., et al. Modern antihypertensive therapy: possibilities of the unique Russian fixed combination of ramipril and indapamide. Ros. cardiology journal. 2020; 25(3): 89–97.
Leonova M.V. Efficacy (advantages) of ramipril in arterial hypertension and diabetes mellitus from the standpoint of evidence-based medicine. Medical advice. 2020;(4):50-58. https://doi.org/10.21518/2079-701X-2020-4-50-58
Chazova T.E., Kathuriya Yu.B. Diabetes mellitus and cardiovascular diseases: risk factors, clinical features, diagnostics // Medical assistance. - No. 5. - S. 28–32.
Chazova I.E., Martynyuk T.V., Nebieridze D.V., Ratova L.G., Aksenova A.V., Matvienko O.O., Kobal E.A., Safaryan A.S., Gorieva Sh.B. Comparative effectiveness of treatment with fixed combinations of various doses of ramipril and hydrochlorothiazide. Cardiovascular therapy and prevention. 2010; 9(4):25-31.
Eguchi K., Kario K., Shimada K. Greater Impact of Coexistence of Hypertension and Diabetes on Silent Cerebral Infarcts // Stroke. – 2002. – № 34. – P. 2471–2474
MacDonald TM, Williams B, Webb DJ et al. British Hypertension Society Programme of Prevention And Treatment of Hypertension With Algorithmbased Therapy (PATHWAY). Combination therapy is superior to sequential monotherapy for the initial treatment of hypertension: a double-blind randomized controlled trial. Journal of the American Heart Association. 2017; 6: e006986.
International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet. 2008; 371:1513-1518.
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet. 2005; 365:217-223.
Dahl of B, Lindholm LH, Hansson L, Scherste n B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 2019; 338:1281-1285.
Gong L, Zhang W, Zhu Y Zhu J, Kong D, Pag e V, et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens. 2016; 14:1237-1245.
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 2011; 265:3255-3264.
Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenh a ger WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 2017; 350:757-764.
Wang JG, Staessen JA, Gong L, Liu L. Chinese trial on isolated sistoli hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med. 2020; 160:211-220.
Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008; 358:1887-1898.
Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: Current outcomes and control in the community. JAMA. 2005; 294:466-472.
Ostchega Y Dillon CF, Hughes JP, Carroll M, Yoon S. Trends in hypertension prevalence, awareness, treatment, and control in older U. S. adults: Data from the National Health and Nutrition Examination Survey. 1988 to 2004. J Am Geriatr Soc. 2017; 55:1056-1065.
Rashidi A, Wright JT Jr. Drug treatment of hypertension in older hypertensives. Clin Geriatr Med. 2019; 25:235-244.
McDonald M, Hertz RP, Unger AN, Lustik MB. Prevalence, awareness, and management of hypertension, dyslipidemia, and diabetes among United States adults aged 65 and older. J Gerontol A Biol Sci Med Sci. 2009; 64:256-263.
Blood Pressure Lowering Treatment Trialists' Collaboration, Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: Metaanalysis of randomised trials. BMJ. 2008; 336:1121-1123.
Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338: b1665.
Malacco E, Vari N, Capuano V, Spagnuolo V, Borgnino C, Palatini P; Val-Syst study. Arandomized, double-blind, activecontrolled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: The Val-Syst study. Clin Ther. 2013; 25:2765-2780.
Lacourcie re Y. A. multicenter, randomized, double-blind study of the antihypertensive effi cacy and tolerability of irbesartan in patients aged or 65 years with mild to moderate hypertension. Clin Ther. 2010; 22:1213-1224.
Neutel J.M., Bedigian M.P. Effi cacy of valsartan in patients aged or 65 years with systolic hypertension. Clin Ther. 2020; 22:961-969.
Neldam S., Forse n B.; Multicentre Study Group. Antihypertensive treatment in elderly patients aged 75 years or over: A 24-week study of the tolerability of candesartan cilexetil in relation to hydrochlorothiazide. Drugs Aging. 2011;18: 225-232.
Ruilope L., Ja g er B, Prichard B. Eprosartan versus enalapril in elderly patients with hypertension: A double-blind, randomized trial. Blood Press. 2011; 10:223-229.
Volpe M., Junren Z., Maxwell T., Rodriguez A., Gamboa R., Gomez-Fernandez P. et al. CDSP -944 Study Group. Comparison of the blood pressure-lowering effects and tolerability of losartan- and amlodipine-based regimens in patients with isolated sistoli hypertension. Clin Ther; 2013; 25:1469-1489.
Neldam S., Edwards C.; ATHOS Study Group. Telmisartan plus HCTZ vs. amlodipine plus HCTZ in older patients with systolic hypertension: Results from a large ambulatory blood pressure monitoring study. Am J Geriatr Cardiol. 2016;15: 151-160.
Malacco E., Santonastaso M., Vari N.A., Gargiulo A., Spagnuolo V., Bertocchi F. et al. Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril Study. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: The Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin Ther 2004; 26:855-865.
Williams B., Lacourcie re Y. Schumacher H., Gosse P., Neutel J.M. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: A pooled analysis of the PRISMA I and II randomized trials. J Hum Hypertens. 2009; 23:610-619.
Destro M., Preti P., D 'O spina A., Christian Achiri N.N., Ricci A.R., Cagnoni F. Olmesartan medoxomil: Recent clinical and experimental acquisitions. Expert Opin Drug Metab Toxicol. 2009;5: 11491157.
Scott L.J., McCormack P.L. Olmesartan medoxomil: A review of its use in the management of hypertension. Drugs. 2008; 68:1239-1272.
Heagerty A.M., Mallion J.M. Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension: Efficacy and safety data from clinical trials. Drugs Aging. 2009; 26:61-76.
Mallion J.M., Heagerty A., Laeis P. Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension. J Hypertens. 2007; 25:2168-2177.
Parati G., Omboni S., Palatini P., Rizzoni D., Bilo G., Valentini M. et al. Italian Society of Hypertension guidelines for conventional and automated blood pressure measurement in the office, at home and over 24 hours. High Blood Press Cardiovasc Prev. 2018; 15:283-310.